TARSUS PHARMACEUTICALS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- TARSUS PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-06-30 was 91.55K shares, a 61.19% increase year-over-year.
- TARSUS PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-03-31 was 45.39K shares, a 42.13% decline year-over-year.
- TARSUS PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-12-31 was 44.88K shares, a 61.14% decline year-over-year.
- TARSUS PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-09-30 was 127.08K shares, a 116.60% increase year-over-year.
- TARSUS PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2025 was 307.19K shares, a 4.94% decline from fiscal 2024.
- TARSUS PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2024 was 323.15K shares, a 137.07% increase from fiscal 2023.
- TARSUS PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2023 was 136.31K shares, a 232.63% increase from fiscal 2022.
- TARSUS PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2022 was 40.98K shares, a 64.19% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 12 month |
|---|---|---|
| 2026-06-30 | 91.55K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | 308.90K shares derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | 45.39K shares 10-Q · filed 2026-05-06 | 274.15K shares derived: sum of 4 quarters · filed 2026-05-06 |
| 2025-12-31 | 44.88K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | 307.19K shares 10-K · filed 2026-02-23 |
| 2025-09-30 | 127.08K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | 377.80K shares derived: sum of 4 quarters · filed 2025-11-04 |
| 2025-06-30 | 56.80K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | 309.39K shares derived: sum of 4 quarters · filed 2025-08-06 |
| 2025-03-31 | 78.44K shares 10-Q · filed 2025-05-01 | 352.27K shares derived: sum of 4 quarters · filed 2025-05-01 |
| 2024-12-31 | 115.49K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | 323.15K shares 10-K · filed 2025-02-25 |
| 2024-09-30 | 58.67K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | 211.78K shares derived: sum of 4 quarters · filed 2024-11-13 |
| 2024-06-30 | 99.68K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | 262.74K shares derived: sum of 4 quarters · filed 2024-08-08 |
| 2024-03-31 | 49.31K shares 10-Q · filed 2024-05-08 | 179.18K shares derived: sum of 4 quarters · filed 2024-05-08 |
| 2023-12-31 | 4.12K shares derived: 10-K 12 month − 3 quarters · filed 2024-02-27 | 136.31K shares 10-K · filed 2024-02-27 |
| 2023-09-30 | 109.63K shares 10-Q · filed 2023-11-09 | |
| 2023-06-30 | 16.12K shares 10-Q · filed 2023-11-09 | |
| 2023-03-31 | 6.44K shares 10-Q · filed 2023-11-09 | |
| 2022-12-31 | 40.98K shares 10-K · filed 2024-02-27 | |
| 2021-12-31 | 24.96K shares 10-K · filed 2023-03-17 | |
| 2020-12-31 | 197.18K shares 10-K · filed 2022-03-14 | |
| 2019-12-31 | 0.00 shares 10-K · filed 2021-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |